Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES JUBILANT LIFE SCIENCES DIVIS LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 60.4 17.3 349.0% View Chart
P/BV x 13.9 3.2 430.6% View Chart
Dividend Yield % 0.4 0.5 95.2%  

Financials

 DIVIS LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
DIVIS LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,639898 182.6%   
Low Rs1,115618 180.6%   
Sales per share (Unadj.) Rs186.3572.0 32.6%  
Earnings per share (Unadj.) Rs51.036.2 140.7%  
Cash flow per share (Unadj.) Rs57.359.5 96.3%  
Dividends per share (Unadj.) Rs16.004.50 355.6%  
Dividend yield (eoy) %1.20.6 195.6%  
Book value per share (Unadj.) Rs261.8301.9 86.7%  
Shares outstanding (eoy) m265.47159.28 166.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.41.3 557.9%   
Avg P/E ratio x27.020.9 129.2%  
P/CF ratio (eoy) x24.012.7 188.7%  
Price / Book Value ratio x5.32.5 209.6%  
Dividend payout %31.412.4 252.8%   
Avg Mkt Cap Rs m365,592120,694 302.9%   
No. of employees `00011.82.4 495.7%   
Total wages/salary Rs m5,42319,260 28.2%   
Avg. sales/employee Rs Th4,175.138,120.6 11.0%   
Avg. wages/employee Rs Th457.78,058.4 5.7%   
Avg. net profit/employee Rs Th1,141.82,414.3 47.3%   
INCOME DATA
Net Sales Rs m49,46391,108 54.3%  
Other income Rs m1,556357 435.5%   
Total revenues Rs m51,01991,466 55.8%   
Gross profit Rs m18,71817,390 107.6%  
Depreciation Rs m1,6893,709 45.5%   
Interest Rs m352,198 1.6%   
Profit before tax Rs m18,55111,840 156.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m5,0233,268 153.7%   
Profit after tax Rs m13,5275,770 234.4%  
Gross profit margin %37.819.1 198.3%  
Effective tax rate %27.127.6 98.1%   
Net profit margin %27.36.3 431.8%  
BALANCE SHEET DATA
Current assets Rs m46,50145,848 101.4%   
Current liabilities Rs m8,46820,897 40.5%   
Net working cap to sales %76.927.4 280.8%  
Current ratio x5.52.2 250.3%  
Inventory Days Days13157 230.3%  
Debtors Days Days8651 168.5%  
Net fixed assets Rs m25,79765,498 39.4%   
Share capital Rs m531159 333.3%   
"Free" reserves Rs m68,96247,930 143.9%   
Net worth Rs m69,49348,089 144.5%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m80,383114,685 70.1%  
Interest coverage x531.06.4 8,314.5%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.8 77.5%   
Return on assets %16.96.9 242.8%  
Return on equity %19.512.0 162.2%  
Return on capital %26.712.4 215.5%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23812,422 332.0%   
Fx outflow Rs m12,40517,227 72.0%   
Net fx Rs m28,833-4,805 -600.1%   
CASH FLOW
From Operations Rs m9,54311,215 85.1%  
From Investments Rs m-6,854-10,118 67.7%  
From Financial Activity Rs m-2,4596,574 -37.4%  
Net Cashflow Rs m2307,612 3.0%  

Share Holding

Indian Promoters % 52.0 45.6 114.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 11.8 8.7 135.6%  
FIIs % 19.0 21.2 89.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.1 81.5%  
Shareholders   31,796 23,815 133.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  VENUS REMEDIES  WYETH  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS